You can buy or sell APTO and other stocks, options, ETFs, and crypto commission-free!
Aptose Biosciences, Inc. Common Shares, also called Aptose Biosciences, is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Read More Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG'806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMar 13
Aptose Biosciences Inc. (APTO) CEO William Rice on Q4 2018 Results - Earnings Call Transcript
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2018 Earnings Conference Call March 12, 2019 5:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President, and CEO Gregory Chow - SVP and CFO Conference Call Participants Mathew Bilger - Oppenheimer Gregory Renza - RBC Capital Markets Joe Pantginis - HC Wainwright John Newman - Canaccord Genuity Limited Operator Good afternoon. My name is Dillon and I’ll be your conference operator today. I would like to welcome...
Simply Wall StMar 8
Could Aptose Biosciences Inc.’s (TSE:APS) Investor Composition Influence The Stock Price?
Every investor in Aptose Biosciences Inc. (TSE:APS) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your portfolio.’ Aptose Biosciences is a smaller company with a market capitalization of CA$89m, ...
-$0.14 per share
-$0.17 per share